INDIA-PHARMACEUTICAL-GILEAD-HEPATITIS

Gregg Alton (C), Executive Vice President for Corporate and Medical Affairs at Gilead Sciences, looks on during a press conference in New Delhi on September 15, 2014. US biotechnology firm Gilead Sciences announced September 15 that it has signed generic licensing deals with seven India-based companies to increase access to its Hepatitis C drugs in the developing world. The non-exclusive agreements allow the companies to make the drug sofosbuvir, known as Sovaldi that is sold at the cost of $1,000 a tablet in the United States, for distribution in 91 developing countries, the company said in a statement. AFP PHOTO/ SAJJAD HUSSAIN (Photo credit should read SAJJAD HUSSAIN/AFP via Getty Images)
Gregg Alton (C), Executive Vice President for Corporate and Medical Affairs at Gilead Sciences, looks on during a press conference in New Delhi on September 15, 2014. US biotechnology firm Gilead Sciences announced September 15 that it has signed generic licensing deals with seven India-based companies to increase access to its Hepatitis C drugs in the developing world. The non-exclusive agreements allow the companies to make the drug sofosbuvir, known as Sovaldi that is sold at the cost of $1,000 a tablet in the United States, for distribution in 91 developing countries, the company said in a statement. AFP PHOTO/ SAJJAD HUSSAIN (Photo credit should read SAJJAD HUSSAIN/AFP via Getty Images)
INDIA-PHARMACEUTICAL-GILEAD-HEPATITIS
PURCHASE A LICENCE
How can I use this image?
AED 1,850.00
AED

DETAILS

Restrictions:
Contact your local office for all commercial or promotional uses. Full editorial rights UK, US, Ireland, Italy, Spain, Canada (not Quebec). Restricted editorial rights elsewhere, please call local office.
Credit:
SAJJAD HUSSAIN / Stringer
Editorial #:
455478868
Collection:
AFP
Date created:
15 September, 2014
Upload date:
Licence type:
Release info:
Not released. More information
Source:
AFP
Barcode:
AFP
Object name:
Del6353129